Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis. (Q38129036)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

7 March 2020

meta-analysis

0 references

title

Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

7 March 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Anja Weiß

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

7 March 2020

Angela Zink

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

7 March 2020

Joachim Listing

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

7 March 2020

publication date

14 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

7 March 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

7 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

2127-2135

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

Mortality Risk by Functional Status and Health-related Quality of Life in Patients with Rheumatoid Arthritis

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Predicting mortality in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

A Dose–Response Meta-Analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KET266

10.1093/RHEUMATOLOGY/KET266

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json

release_rh6napyvqbdglgpsdmac7v2jmi

7 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rh6napyvqbdglgpsdmac7v2jmi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23946435 AND SRC:MED&resulttype=core&format=json